Tags

Type your tag names separated by a space and hit enter

Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential.
Curr Stem Cell Res Ther. 2021; 16(2):105-108.CS

Abstract

A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus (COVID-19). With the rapid increase of infected patients and deaths, it is vital to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patients; some of the them will develop acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, and even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs used during the outbreak.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Xiong J
Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.
Bao L
Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.
Qi H
The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Feng Z
Bayi Children's Hospital, The Seventh Medical Center, PLA General Hospital, Beijing, China.
Shi Y
Department of Neonatology, Ministry of Education Key Laboratory of Child Development and Disorders; National Clinical Research Center for Child Health and Disorders; China International Science and Technology Cooperation base of Child development and Critical Disorders; Children's Hospital of Chongqing Medical University; Chongqing Key Laboratory of Pediatrics, Chongqing, 400014, China.

MeSH

AnimalsCOVID-19ChinaClinical Trials as TopicHumansMesenchymal Stem Cell TransplantationMesenchymal Stem CellsPandemicsSARS-CoV-2

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32479246

Citation

Xiong, Jing, et al. "Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential." Current Stem Cell Research & Therapy, vol. 16, no. 2, 2021, pp. 105-108.
Xiong J, Bao L, Qi H, et al. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. Curr Stem Cell Res Ther. 2021;16(2):105-108.
Xiong, J., Bao, L., Qi, H., Feng, Z., & Shi, Y. (2021). Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. Current Stem Cell Research & Therapy, 16(2), 105-108. https://doi.org/10.2174/1574888X15666200601152832
Xiong J, et al. Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. Curr Stem Cell Res Ther. 2021;16(2):105-108. PubMed PMID: 32479246.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mesenchymal Stem Cell-Based Therapy for COVID-19: Possibility and Potential. AU - Xiong,Jing, AU - Bao,Lei, AU - Qi,Hongbo, AU - Feng,Zhichun, AU - Shi,Yuan, PY - 2020/03/15/received PY - 2020/04/24/revised PY - 2020/04/27/accepted PY - 2020/6/2/pubmed PY - 2021/2/24/medline PY - 2020/6/2/entrez KW - Mesenchymal stem cells KW - acute respiratory distress syndrome KW - coronavirus disease 2019 KW - cytokine KW - dysfunction KW - syndrome SP - 105 EP - 108 JF - Current stem cell research & therapy JO - Curr Stem Cell Res Ther VL - 16 IS - 2 N2 - A novel coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV- 2) has emerged in Wuhan, China since the end of December 2019 and has quickly spread all over the world in a matter of two months. To date, no specific treatment has been proven to be effective for coronavirus (COVID-19). With the rapid increase of infected patients and deaths, it is vital to explore an effective treatment for COVID-19. Current studies suggest that there exists cytokine storm in SARS-CoV-2-infected patients; some of the them will develop acute respiratory distress syndrome (ARDS) and multiple organ dysfunction, and even death. Mesenchymal stem cells (MSCs) possess the property of immunomodulation. Given the previous preclinical and clinical studies, MSCs therapy has shown safety and efficacy in the treatment of respiratory failure or ARDS. Based on similar principles, MSCs therapy may also be an effective therapy in the treatment of COVID-19. In this study, we summarized the clinical outcomes of MSCs for ARDS patients in some preclinical and clinical studies and discussed the application of MSCs for patients with COVID-19 in China and the related important issues with MSCs used during the outbreak. SN - 2212-3946 UR - https://www.unboundmedicine.com/medline/citation/32479246/Mesenchymal_Stem_Cell_Based_Therapy_for_COVID_19:_Possibility_and_Potential_ DB - PRIME DP - Unbound Medicine ER -